AN OVERVIEW ON TUBULARCULOSIS TREATMENT IN CURRENT SCENARIO

  • AMIT BUDHORI Department of Pharmacy, Devsthali Vidyapeeth, College of Pharmacy, Rudrapur, Uttarakhand, India.
  • ABHISHEK TIWARI Department of Pharmacy, Devsthali Vidyapeeth, College of Pharmacy, Rudrapur, Uttarakhand, India.
  • VARSHA TIWARI Department of Pharmacy, Devsthali Vidyapeeth, College of Pharmacy, Rudrapur, Uttarakhand, India.
  • MANISH KUMAR Department of Pharmaceutics, M.M. College of Pharmacy, Ambala, Haryana, India.

Abstract

The causative agent of tuberculosis (TB) is Mycobacterium tuberculosis, which mainly infects lungs and causes severe, fever, weight loss, chest pain, etc. It is an extremely transmittable disease spreaded throughout the world as per the WHO. It has emerged as new threat and drug resistance strains of Mycobacterium are emerging throws a challenge to human’s health like Covid-19 in current scenario. TB is now come in the form of bone TB, which is very difficult to diagnosis due to very slow-growing characteristics of Mycobacterium. This review highlights the history, drug development, current treatment both allopathic and Ayurvedic, as well as novel drugs available for the treatment of drug resistance Mycobacterium.

Keywords: Tuberculosis, Nix-tuberculosis, Extensively drug-resistant-tuberculosis, Mycobacterium tuberculosis, Ayurvedic

References

1. Sharma SK, Mohan A. Multidrug-resistant tuberculosis. Indian J Med Res 2004;120:354-76.
2. Tripathi KD. Essentials of Medical Pahramacology. 7th ed. New Delhi: Jaypee Brothers Medical Publications Ltd.; 2008. p. 739-48.
3. Zaleskis R. Adverse effects of antituberculosis chemotherapy. Eur Respir Dis 2006;5:47-9.
4. Jain RC. Anti-tubercular activity of garlic oil. Indian Drugs 1993;30:73-5.
5. Bruce WG. Investigations of antibacterial activity in the aloe. S Afr Med J 1967;41:984.
6. Tandon VR, Khajuria V, Kapoor B, Kour D, Gupta S. Hepatoprotective activity of Vitex negundo leaf extract against anti-tubercular drugs induced hepatotoxicity. Fitoterapia 2008;79:533-8.
7. Sinha K, Mishra NP, Singh J, Khanuja SP. Tinospora cordifolia, a reservoir plant for therapeutic applications: A review. Indian J Tradit Knowledge 2004;3:257-70.
8. Promsawan N, Kittakoop P, Boonphong S, Nongkunsarn P. Anti-tubercular cassane furanoditerpenoids from the roots of Caesalpinia pulcherrima. Planta Med 2003;69:776-7.
9. Rai KP, Mehtha S, Gupta RK, Watwal G. A novel antimicrobial agents Trichosanthes dioica. Int J Pharma Bio Sci 2010;1:1-9.
10. Ubaid RS, Anantrao KM, Juju JB, Mateenuddin MD. Effect of Ocimum sanctum leaf extract on hepatotoxicity induced by anti-tubercular drugs in rats. Indian J Physiol Pharmacol 2003;47:465-70.
11. Sehgal J, Siddheswaran P, Kumar SK, Karthiyayini T. Anti-tubercular activity of fruits of Prunus armeniaca (L.). Int J Pharma Bio Sci 2010;1:1-4.
12. Saludes JP, Garson MJ, Franzblau SG, Aguinaldo AM. Anti-tubercular constituents from the hexane fraction of Morinda citrifolia Linn. (Rubiaceae). Phytother Res 2002;16:683-5.
13. Koul A, Vranckx L, Dendouga N, Balemans W, Van den Wyngaert I, Vergauwen K, et al. Diarylquinolines are bactericidal for dormant Mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 2008;283:25273-80.
14. Andries K, Villellas C, Coeck N, Thys K, Gevers I, Vranckx L, et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One 2014;9:e102135.
15. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Recomm Rep 2013;62:1-12.
16. Diacon AH, Pym A, Grobusch M, Patientia, R, Rustomjee R, Page- Shipp L, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360:2397-405.
17. Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014;58:2979-81.
18. Tasneen R, Li SY, Peloquin CA, Taylor D, Williams KN, Andries K, et al. Sterilizing activity of novel TMC207-and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 2011;55:5485-92.
19. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014;371:723-32.
20. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, et al. 14-day bactericidal activity of PA- 824, bedaquiline, pyrazinamide, and moxifloxacin combinations: A randomised trial. Lancet 2012;380:986-93.
21. Van BF, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: Comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009;32:359-78.
22. Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, et al. Sterilizing activities of novel combinations lacking first-and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2012;56:3114-20.
23. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera- Rivero JL, Vargas-Vasquez DE, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366:2151-60.
24. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006;3:e466.
25. Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013;41:1393-400.
26. Singh R, Manjunatha U, Boshoff HI. PA-824 kills non-replicating Mycobacterium tuberculosis by intracellular NO release. Science 2008;322:1392-5.
27. Manjunatha U, Boshoff HI, Barry CE. The mechanism of action of PA-824 novel insights from transcriptional profiling. Commun Integr Biol 2009;2:215-8.
28. Somasundaram S, Anand RS, Venkatesan P, Paramasivan CN. Bactericidal activity of PA-824 against Mycobacterium tuberculosis under anaerobic conditions and computational analysis of its novel analogues against mutant Ddn receptor. BMC Microbiol 2013;13:218-8.
29. Stover CK, Warrener P, Van Devanter DR, Arain TM, Langhorne MH, Anderson SW, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000;405:962-6.
30. Tyagi S, Nuermberger E, Yoshimatsu T, Williams K, Rosenthal I, Lounis N, et al. Bactericidal activity of the nitroimidazopyran PA- 824 in a murine model of tuberculosis. Antimicrob Agents Chemother 2005;49:2289-93.
31. Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob Agents Chemother 2009;53:3720-5.
32. Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, Tompkins NM, et al. Preclinical testing of the nitroimidazopyran PA- 824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 2005;49:2294-301.
33. Manjunatha UH, Boshoff H, Dowd CS, Zhang L, Albert TJ, Norton JE, et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 2006;103:431-6.
34. Feuerriegel S, Köser CU, Baù D, Rüsch-Gerdes S, Summers DK, Archer JA, et al. Impact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824. Antimicrob Agents Chemother 2011;55:5718-22.
35. Hu Y, Coates AR, Mitchison DA. Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2008;12:69-73.
36. Hartkoorn RC, Ryabova OB, Chiarelli LR, Riccardi G, Makarov V, Cole ST. Mechanism of action of 5-nitrothiophenes against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014;58:2944-7.
37. Diacon AH, Dawson R, Hanekom M, Narunsky K, Maritz SJ, Venter A, et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother 2010;54:3402-7.
38. Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK. Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects. Antimicrob Agents Chemother 2009;53:3726-33.
39. Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, Donald PR, et al. Phase II dose-ranging trial of the early bactericidal activity of PA- 824. Antimicrob Agents Chemother 2012;56:3027-31.
40. Yip PC, Kam KM, Lam ET, Chan RC, Yew WW. In vitro activities of PNU-100480 and linezolid against drug-susceptible and drug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents 2013;42:96-7.
41. Barbachyn MR, Hutchinson DK, Brickner SJ, Cynamon MH, Kilburn JO, Klemens SP, et al. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J Med Chem 1996;39:680-5.
42. Wallis RS, Dawson R, Friedrich SO, Venter A, Paige D, Zhu T, et al. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS One 2014;9:e94462.
43. Wallis RS, Jakubiec W, Kumar V, Bedarida G, Silvia A, Paige D, et al. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob Agents Chemother 2011;55:567-74.
44. Balasubramanian V, Solapure S, Iyer H, Ghosh A, Sharma S, Kaur P, et al. Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis. Antimicrob Agents Chemother 2014;58:495-502.
45. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012;367:1508-18.
46. Zanetti S, Cannas S, Molicotti P, Bua A, Cubeddu M, Porcedda S, et al. Evaluation of the antimicrobial properties of the essential oil of Myrtus communis L. Against clinical strains of Mycobacterium spp. Interdiscip Perspect Infect Dis 2010;2010:931530.
47. Anandan R, Jayakar B, Karar B, Babuji S, Manavalan R, Kumar RS. Effect of ethanol extract of flowers of Vitex trifolia Linn. On CCl4 induced hepatic injury in rats. Pak J Pharm Sci 2009;22:391-4.
48. Sharma S, Kumar M, Sharma S, Nargotra A, Koul S, Khan IA. Piperine as an inhibitor of Rv1258c, a putative multidrug efflux pump of Mycobacterium tuberculosis. Antimicrob Chemother 2010;65:1694-701.
49. Ghosal S, Biswas K, Chaudhuri RK. Chemical constituents of gentianaceae XXIV: Anti-Mycobacterium tuberculosis activity of naturally occurring xanthones and synthetic analogs. J Pharm Sci 1978;67:721-2.
50. Rojas R, Caviedes L, Aponte JC, Vaisberg AJ, Lewis WH, Lamas G, et al. Aegicerin, the first oleanane triterpene with wide-ranging antimycobacterial activity, isolated from Clavija procera. J Nat Prod 2006;69:845-6.
51. Limsuwan S, Trip EN, Kouwen TR, Piersma S, Hiranrat A. Rhodomyrtone: A new candidate as natural antibacterial drug from Rhodomyrtus tomentosa. Phytomedicine 2009;16:645-51.
52. Leon-Diaz R, Meckes M, Said-Fernandez S, Molina-Salinas GM, Vargas-Villarreal J, Torres J, et al. Antimycobacterial neolignans isolated from Aristolochia taliscana. Mem Inst Oswaldo Cruz 2010;105:45-51.
53. Gupta VK, Shukla C, Bisht GR, Saikia D, Kumar S, Thakur RL. Detection of antituberculosis activity in some folklore plants by radiometric BACTEC assay. Lett Appl Microbiol 2011;52:33-40.
54. Mativandlela SP, Muthivhi T, Kikuchi H, Oshima Y, Hamilton C, Hussein AA, et al. Antimycobacterial flavonoids from the leaf extract of Galenia Africana. J Nat Prod 2009;72:2169-71.
55. Higuchi CT, Sannomiya M, Roberto S, Sacramento LV, Sato DN. Triterpenes and anti-tubercular activity of Byrsonima crassa. Quim Nova 2008;31:1719-21.
56. Lall N, Meyer JJ. In vitro inhibition of drug-resistant and drug-sensitive strains of Mycobacterium tuberculosis by ethnobotanically selected South African plants. J Ethnopharmacol 1999;66:347-54.
57. Sehlapelo BM, Drewes SE, Scott-Shaw R. A 6-substituted 5,6-dihydro- ?-pyrone from two species of Cryptocarya. J Plant Biochem 1994;37:847-9.
58. Fai YM, Yeung CK, Tao CC, Shan B, Yeung RC, Shan H, et al. Phytochemical study of a potential anti-tubercular Ti?n medicinal plant Gentianopsis paludosa. Nat Proda Med 2008;1:2-9.
59. Bapela MJ, Lall N, Isaza-Martinez JH, Regnier T, Meyer JJ. Variation in the content of naphthoquinones in seeds and seedlings of Euclea natalensis. South Afr J Bot 2007;73:606-10.
60. Sobhy EA, Feky SS. Chemical constituents and antimicrobial activity of Helichrysum stoechas. Asian J Plant Sci 2007;6:692-5.
61. Koyama J. Anti-infective quinone derivatives of recent patents. Recent Pat Antiinfect Drug Discov 2006;1:113-25.
62. Imelouane B, Amhamdi H, Wathelet JP, Ankit M, Khedid K, Bachiri A. Chemical composition and antimicrobial activity of essential oil of thyme (Thymus vulgaris) from Eastern Morocco. Int J Agric Bio 2009;11:205-8.
63. Bamuamba K, Gammon DW, Meyers P, Dijoux-Franca MG. Anti-mycobacterial activity of five plant species used as traditional medicines in the Western Cape Province (South Africa). J Ethnopharmacol 2008;117:385-90.
64. Chen Y, Tao Y, Lian X, Wang L, Zhao Y, Jiang J, et al. Chemical constituents of Angiopteris esculenta including two new natural lactones. Food Chem 2010;122:1173-5.
65. Topcu G, Goren AC. Biological activity of diterpenoids isolated from Anatolian Lamiaceae plants. Rec Nat Prod 2007;1:1-16.
66. Normala H, Suhaimi MI. Quantification of total phenolics in different parts of Pluchea indica (Less) ethanolic and water extracts. Pertanika J Sci Technol 2011;19:19-24.
67. Jha MK, Alam MB, Hossain MS, Islam A. In vitro antioxidant and cytotoxic potential of Costus speciosus (koen.) smith rhizome. IJPSR 2010;1:138-44.
68. Mativandlela SP, Lall N, Meyer JJ. Antibacterial, antifungal and anti-tubercular activity of (the roots of) Pelargonium reniforme (CURT) and Pelargonium sidoides (DC) (Geraniaceae) root extracts. South Afr J Bot 2006;72:232-7.
69. Henriques AT, Melo AA, Moreno PR, Ene LL, Henriques JA, Schapoval EE. Ervatamia coronaria: Chemical constituents and some pharmacological activities. J Ethnopharmacol 1996;50:19-25.
70. Gu JQ, Wang Y, Franzblau SG, Montenegro G, Timmermann BN. Constituents of Senecio chionophilus with potential anti-tubercular activity. J Nat Prod 2004;67:1483-7.
71. Jian-Qiao G, Wang Y, Franzblau SG, Montenegro G, Timmermann BN. Constituents of Quinchamalium majus with potential antitubercular activity. Z Naturforsch 2004;59:797-802.
72. Arya V. A review on anti-tubercular plants. Int J Pharmtech Res 2011;3:872-80.
73. Barrows LR, Powan E, Pond CD, Matainaho T. Anti-TB activity of Evodia elleryana bark extract. Fitoterapia 2007;78:250-2.
Statistics
40 Views | 47 Downloads
Citations
How to Cite
BUDHORI, A., A. TIWARI, V. TIWARI, and M. KUMAR. “AN OVERVIEW ON TUBULARCULOSIS TREATMENT IN CURRENT SCENARIO”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 13, no. 12, Dec. 2020, pp. 17-20, doi:10.22159/ajpcr.2020.v13i12.39163.
Section
Review Article(s)